Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Andi Leubitz"'
Autor:
Kate Banks, Ming‐yi Hu, Andi Leubitz, Kaela M. Porter, Paul Goodyer, David J. Wyatt, Thomas Haverty
Publikováno v:
Journal of Clinical Pharmacology
The aim of this study was to assess the pharmacokinetics (PK) and safety of ELX‐02 in a renally impaired population and apply these findings to the individualized dosing of patients with nephropathic cystinosis. This phase 1 renal impairment (RI; m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3788bce125abdd0467c7313518e8e65b
https://doi.org/10.1002/jcph.1807
https://doi.org/10.1002/jcph.1807
Autor:
Andi Leubitz, Kate Banks, Kaela M. Porter, Frederic Vanhoutte, Ming‐yi Hu, Kathleen Campbell, Kathleen Tencer, Tom Haverty, Efrat Gordon
Publikováno v:
Clinical Pharmacology in Drug Development
ELX‐02 is an investigational compound being developed as a therapy for genetic diseases caused by nonsense mutations such as cystic fibrosis. Structurally, ELX‐02 is an aminoglycoside analogue that induces read‐through of nonsense mutations thr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bc9c030d75a52de550ecdf3e8efe896
https://pubmed.ncbi.nlm.nih.gov/33465285
https://pubmed.ncbi.nlm.nih.gov/33465285
Publikováno v:
Journal of Cystic Fibrosis. 18:S128
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5dd3b421882339b287090af7cb5ee5b
https://doi.org/10.1016/s1569-1993(19)30544-2
https://doi.org/10.1016/s1569-1993(19)30544-2
Publikováno v:
Journal of Cystic Fibrosis. 18:S11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c67683c4689dfb5a7a0142ff7e24fbc
https://doi.org/10.1016/s1569-1993(19)30150-x
https://doi.org/10.1016/s1569-1993(19)30150-x